Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS
This may happen after intense physical activity, injury, or even prolonged poor posture
Together this phenomenon is collectively referred to as the gray market. This gray market is not subject to the quality control regulations that govern the pharmaceutical industry, and testing conducted on a range of peptides including MOTS-c, BPC-157, TB-500, and CJC-1295 by The New Yorker in April showed that many were impure or contained less than the advertised dose
Therefore, the formulation supports stable storage, consistent handling, and repeatable results across research protocols when stored under appropriate conditions
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R
Supporting Study: Maquart, F
US$ 27.88
US$ 21.32
US$ 25.19
